Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2010 1
2012 1
2014 3
2016 1
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
EphA3 biology and cancer.
Janes PW, Slape CI, Farnsworth RH, Atapattu L, Scott AM, Vail ME. Janes PW, et al. Among authors: Vail ME. Growth Factors. 2014 Dec;32(6):176-89. doi: 10.3109/08977194.2014.982276. Epub 2014 Nov 13. Growth Factors. 2014. PMID: 25391995 Review.
Antibody Targeting of Eph Receptors in Cancer.
Janes PW, Vail ME, Gan HK, Scott AM. Janes PW, et al. Among authors: Vail ME. Pharmaceuticals (Basel). 2020 May 8;13(5):88. doi: 10.3390/ph13050088. Pharmaceuticals (Basel). 2020. PMID: 32397088 Free PMC article. Review.
An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth.
Atapattu L, Saha N, Chheang C, Eissman MF, Xu K, Vail ME, Hii L, Llerena C, Liu Z, Horvay K, Abud HE, Kusebauch U, Moritz RL, Ding BS, Cao Z, Rafii S, Ernst M, Scott AM, Nikolov DB, Lackmann M, Janes PW. Atapattu L, et al. Among authors: Vail ME. J Exp Med. 2016 Aug 22;213(9):1741-57. doi: 10.1084/jem.20151095. Epub 2016 Aug 8. J Exp Med. 2016. PMID: 27503072 Free PMC article.
Hypoxia-controlled EphA3 marks a human endometrium-derived multipotent mesenchymal stromal cell that supports vascular growth.
To C, Farnsworth RH, Vail ME, Chheang C, Gargett CE, Murone C, Llerena C, Major AT, Scott AM, Janes PW, Lackmann M. To C, et al. Among authors: Vail ME. PLoS One. 2014 Nov 24;9(11):e112106. doi: 10.1371/journal.pone.0112106. eCollection 2014. PLoS One. 2014. PMID: 25420155 Free PMC article.
Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment.
Vail ME, Murone C, Tan A, Hii L, Abebe D, Janes PW, Lee FT, Baer M, Palath V, Bebbington C, Yarranton G, Llerena C, Garic S, Abramson D, Cartwright G, Scott AM, Lackmann M. Vail ME, et al. Cancer Res. 2014 Aug 15;74(16):4470-81. doi: 10.1158/0008-5472.CAN-14-0218. Cancer Res. 2014. PMID: 25125683 Free article.
PTP1B regulates Eph receptor function and trafficking.
Nievergall E, Janes PW, Stegmayer C, Vail ME, Haj FG, Teng SW, Neel BG, Bastiaens PI, Lackmann M. Nievergall E, et al. Among authors: Vail ME. J Cell Biol. 2010 Dec 13;191(6):1189-203. doi: 10.1083/jcb.201005035. Epub 2010 Dec 6. J Cell Biol. 2010. PMID: 21135139 Free PMC article.
Antibodies binding the ADAM10 substrate recognition domain inhibit Eph function.
Atapattu L, Saha N, Llerena C, Vail ME, Scott AM, Nikolov DB, Lackmann M, Janes PW. Atapattu L, et al. Among authors: Vail ME. J Cell Sci. 2012 Dec 15;125(Pt 24):6084-93. doi: 10.1242/jcs.112631. Epub 2012 Oct 29. J Cell Sci. 2012. PMID: 23108669 Free PMC article.
Over-expression of insulin-like growth factor binding protein-related protein-1(IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis.
Sprenger CC, Vail ME, Evans K, Simurdak J, Plymate SR. Sprenger CC, et al. Among authors: Vail ME. Oncogene. 2002 Jan 3;21(1):140-7. doi: 10.1038/sj.onc.1205021. Oncogene. 2002. PMID: 11791184 Free article.